Why the study?
Does substituting naproxen for ASA reduce gastrointestinal microbleeding in normal volunteers with salicylate-induced bleeding?
Does substituting naproxen for ASA reduce gastrointestinal microbleeding in normal volunteers with salicylate-induced bleeding?
Substituting naproxen for ASA rapidly reduces salicylate-induced gastrointestinal microbleeding to normal levels in healthy volunteers.
May support naproxen substitution in ASA users with microbleeding; confirms rapid normalization in RCT of healthy volunteers.
This study was undertaken to determine if substitution of naproxen for ASA does influence salicylate-induced gastrointestinal bleeding. Twelve normal volunteers were selected and given increasing doses of salicylate until guaiac tests were consistently positive. Autologous labeling of their red blood cells with 51-Cr was used to quantitate the microbleeding. After two weeks on ASA, six subjects were double blindly switched to naproxen and six to placebo for another two weeks of observation. Two-way analysis of variance on the raw data shows a significant treatment effect associated with a significant interaction in both groups. Final analysis on a logarithmic scale permits orthogonal contrasts to be accurately made without any significant remaining interaction. It is concluded that substitution of naproxen for ASA at a dose of 500 mg daily is accompanied by a rapid reduction of microbleeding to "normal" levels.
No takes yet. Share an insight, caveat, or question.
Arsenault et al. (1975) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: